12/26
02:02 am
blrx
BioLineRx Ltd. (NASDAQ: BLRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
BioLineRx Ltd. (NASDAQ: BLRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
12/18
02:03 am
blrx
BioLineRx Ltd. (NASDAQ: BLRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
BioLineRx Ltd. (NASDAQ: BLRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
12/10
08:42 am
blrx
Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors [Yahoo! Finance]
Medium
Report
Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors [Yahoo! Finance]
12/10
02:03 am
blrx
BioLineRx Ltd. (NASDAQ: BLRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Low
Report
BioLineRx Ltd. (NASDAQ: BLRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
12/2
03:01 am
blrx
BioLineRx Ltd. (NASDAQ: BLRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Low
Report
BioLineRx Ltd. (NASDAQ: BLRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
11/26
10:15 am
blrx
BioLine Rx Ltd (BLRX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Shifts [Yahoo! Finance]
Low
Report
BioLine Rx Ltd (BLRX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Shifts [Yahoo! Finance]
11/25
12:17 pm
blrx
BioLineRx Ltd. (NASDAQ: BLRX) had its price target lowered by analysts at HC Wainwright from $21.00 to $9.00. They now have a "buy" rating on the stock.
Low
Report
BioLineRx Ltd. (NASDAQ: BLRX) had its price target lowered by analysts at HC Wainwright from $21.00 to $9.00. They now have a "buy" rating on the stock.
11/25
07:19 am
blrx
BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value [Yahoo! Finance]
Medium
Report
BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value [Yahoo! Finance]
11/25
07:00 am
blrx
BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value
Medium
Report
BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value
11/24
03:31 am
blrx
BioLineRx Ltd. (NASDAQ: BLRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Low
Report
BioLineRx Ltd. (NASDAQ: BLRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
11/21
06:30 am
blrx
BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.
High
Report
BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.
11/20
07:19 am
blrx
BioLineRx to Report Third Quarter 2024 Results on November 25, 2024
Medium
Report
BioLineRx to Report Third Quarter 2024 Results on November 25, 2024
11/16
03:06 am
blrx
BioLineRx Ltd. (NASDAQ: BLRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
BioLineRx Ltd. (NASDAQ: BLRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
11/6
08:06 am
blrx
BioLineRx Ltd. (NASDAQ: BLRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
Medium
Report
BioLineRx Ltd. (NASDAQ: BLRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
11/5
09:00 am
blrx
BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024
Low
Report
BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024
10/31
02:04 am
blrx
BioLineRx Ltd. (NASDAQ: BLRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Low
Report
BioLineRx Ltd. (NASDAQ: BLRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
10/23
02:06 am
blrx
BioLineRx Ltd. (NASDAQ: BLRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
BioLineRx Ltd. (NASDAQ: BLRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
10/16
09:18 am
blrx
BioLineRx receives USPTO allowance of new composition of matter patent on motixafortide [Seeking Alpha]
Medium
Report
BioLineRx receives USPTO allowance of new composition of matter patent on motixafortide [Seeking Alpha]
10/16
07:00 am
blrx
BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide
High
Report
BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide
10/15
02:07 am
blrx
BioLineRx Ltd. (NASDAQ: BLRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
BioLineRx Ltd. (NASDAQ: BLRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.